PharmatecaPharmatecaФарматека2073-40342414-9128Bionika Media31286910.18565/pharmateca.2020.11.14-20ArticlesСтатьиReview ArticleCurrent therapy strategy for metastatic BRAF-positive skin melanomaСовременная стратегия терапии метастатической BRAF-положительной меланомы кожиPolyakovA. PПоляковА. ПMordovskyAleksandr V.МордовскийА. В

Researcher at the Department of Microsurgery

науч. сотр. отделения микрохирургии

alexmord@live.comP.A. Hertsen Moscow Oncology Research Institute - Branch of the National Medical Research Radiological CenterМосковский научно-исследовательский онкологический институт им. П.А. Герцена - филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» МЗ РФ201020202711VOL 27, NO11 (2020)ТОМ 27, №11 (2020)142003032023Copyright ©; 2020, Bionika MediaCopyright ©; 2020, ООО «Бионика Медиа»2020Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/2073-4034/article/view/312869

This review summarizes data from studies on the use of a combination of targeted drugs in the treatment of metastatic BRAF-positive skin melanoma. The addition of a MEK inhibitor to a BRAF inhibitor slows tumor growth, delays acquired resistance, and inhibits paradoxical activation of the MAPK pathway in patients with melanoma and BRAF gene mutation.

В представленном кратком обзоре обобщены данные исследований применения комбинации таргетных препаратов в терапии метастатической BRAF-положительной меланомы кожи. Добавление ингибитора MEK к ингибитору BRAF замедляет рост опухоли, задерживает приобретенную резистентность и ингибирует парадоксальную активацию пути MAPK у пациентов с меланомой и мутацией в BRAF гене.

BRAFMEKmelanomaBRAFMEKtargeted therapyмеланоматаргетная терапияde Vries E. Bray F.I. Coebergh J.W. et al. Changing epidemiology of malignant cutaneous melanoma in Europe 1953-1997: rising trends in incidence and mortality but recent stabilizations in western Europe and decreases in Scandinavia. !nt J Cancer. 2003;107:119-26. doi: 10.1002/ijc.11360.Siegel R, DeSantis C., Virgo K., et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62:220-41. doi: 10.3322/ caac.21149.Hodi FS, O’Day S.J., McDermott D.F., et al. improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-23. doi: 10.1056/ NEJMoa1003466.Robert C, Thomas L., Bondarenko i., et al. ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517-26. doi: 10.1056/ NEJMoa1104621.Wan PIT., Garnett M.J., Roe S.M., et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;16(6):855-67. doi: 10.1016/s0092-8674(04)00215-6.Davies H, Bignell G.R., Cox C., et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-54. doi: 10.1038/nature00766.Ascierto PA, Kirkwood J.M., Grob J.J., et al. The role of BRAF V600 mutation in melanoma. J Transl Med. 2012;10:85. Doi:10.1186/1479-5876-10-85.Curtin J.A., Fridlyand J., Kageshita T., et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353:2135-47. Doi: 10.1056/ NEJMoa050092.Cheng L., Lopez-Beltran A., Massari F, et al. Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. Mod Pathol. 2018;31(1):24-38. Doi:10.1038/modpathol.2017.104.Клинические рекомендации Министерства Здравоохранения « Мел кожи и слизистых оболочек» 2020 (одобрены НПС при Минздраве России 17 июля 2020 г). Доступно по ссылке: https://melanomapro.ru/uploads/ docs/CR_melanoma_2020_final_compressed. pdfСтрояковский Д.Л., Абрамов М.Е., Демидов Л.В. и др. Практические рекомендации по лекарственному лечению меланомы кожи. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2. 2019;9:243-58.Tsai J., Lee J.T., Wang W., et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA. 2008;105(8):3041-46. doi: 10.1073/ pnas.0711741105.Bradish J.R., Cheng L. Molecular pathology of malignant melanoma: changing the clinical practice paradigm toward a personalized approach. Hum Pathol 2014;45:1315-26. doi: 10.1016/j. humpath.2014.04.001.National Comprehensive Cancer Network (NCCN). Practice Guidelines in Oncology: Melanoma Version 1, Available from: https://www.nccn.org/ professionals/physician_gls/pdf/melanoma.pdfMerkel E.A., Gerami P Malignant melanoma of sun-protected sites: a review of clinical, histological, and molecular features. Lab invest. 2017;97:630-doi: 10.1038/labinvest.2016.147.Long G.V, Menzies A.M., Nagrial A.M., et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011;29:1239-46. doi: 10.1200/ JCO.2010.32.4327.Chapman PB., Hauschild A., Robert C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-16. doi: 10.1056/ NEJMoa1103782.Hauschild A., Grob J.J., Demidov L.V. et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358-65. doi: 10.1016/S0140-6736(12)60868-X.Chapman PB. Mechanisms of resistance to RAF inhibition in melanomas harboring a BRAF mutation Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e80.Shi H., Hugo W., Kong X., et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014;4(1):80-doi: 10.1158/2159-8290.CD-13-0642.Kim K.B., Kefford R., Pavlick A.C., et al. Phase ii study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol. 2013;31(4):482-89. Doi: 10.1200/JCO.2012.43.5966.Dhomen N., Marais R. BRAF signaling and targeted therapies in melanoma. Hematol Oncol Clin North Am. 2009;23:529-45. doi: 10.1016/j. hoc.2009.04.001.Eroglu Z., Ribas A. Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy. Ther Adv Med Oncol. 2016;8:48-56.Ribas A., Gonzalez R., Pavlick A., et al. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study [published correction appears in Lancet Oncol. 2014;15(10):417. Lancet Oncol. 2014;15(9):954-65.Paraiso K.H., Fedorenko i.V, Cantini L.P, et al. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer. 2010;102(12):1724-1730. Doi: 10.1038/sj.bjc.6605714.Larkin J., Ascierto P.A., Dreno B., et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867-doi: 10.1056/NEJMoa1408868.McArthur, G.A., et al. 5-year survival update of cobimetinib plus vemurafenib BRAF V600 mutation-positive advanced melanoma: final analysis of the coBRIM study. in 16th international Congress of the Society for Melanoma Research. 2019. Salt Lake City, UT, USA.Larkin J.M.G., Yan Y, McArthur G.A., Ascierto PA. Update of progression-free survival and correlative biomarker analysis from coBRiM: cobimetinib plus vemurafenib in advanced BRAF-mutated melanoma. ASCO, Chicago, iL, USA. 2015. abstract No9006. URL: http://meetinglibrary.asco. org/node/2002036McArthur G.A., Ascierto P.A., Larkin J., Ribas A. LBA5_PR - Phase 3, Double-blind, Placebo-controlled Study of Vemurafenib Versus Vemurafenib+Cobimetinib in Previously Untreated BRAFV600 Mutation-Positive Patients With Unresectable Locally Advanced or Metastatic Melanom. Ann Oncol. 2014; 25(5):1-41.Sanlorenzo M., Choudhry A., Vujic i., et al. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. J Am Acad Dermatol. 2014;71(6):1102-09.e1. doi: 10.1016/j.jaad.2014.09.002.Gutzmer R, Stroyakovskiy D., Gogas H., et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutationpositive melanoma (iMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2020;395:1835-44. doi: 10.1016/ S0140-6736(20)30934-X